By Staff Reporter
NEW YORK – A team from Washington University, the Pacific Northwest National Laboratory, and elsewhere has identified immune subgroups in glioblastoma (GBM) that may ultimately help in developing more effective immunotherapy approaches against aggressive brain cancer.
